Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort

Journal of Immunological Methods

Volumn 310, Issue 1-2, 2006, Pages 20-29

  McKay, Fiona ^a   Schibeci, Stephen ^a   Heard, Robert ^a   Stewart, Graeme ^a   Booth, David ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bioactivity; Interferon beta; Multiple sclerosis; MxA; Neutralizing antibodies

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ARTICLE; AUSTRALIA AND NEW ZEALAND; BIOASSAY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES; AUSTRALASIA; CELL LINE, TUMOR; COHORT STUDIES; CYTOPATHOGENIC EFFECT, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

ORTHOMYXOVIRIDAE;

EID: 33644863225     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2005.11.011     Document Type: Article

References (33)

1. J.L. Ambrus, J.L. Ambrus Jr., S. Chadha, D. Novick, M. Rubinstein, B. Gopalakrishnan, Z. Bernstein, R.L. Priore, and K.C. Chadha Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis Res. Commun. Mol. Pathol. Pharmacol. 96 1997 255
2. A. Bertolotto, S. Malucchi, A. Sala, G. Orefice, P.B. Carrieri, M. Capobianco, E. Milano, F. Melis, and M.T. Giordana Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory J. Neurol. Neurosurg. Psychiatry 73 2002 148
3. A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R.L. Lindberg, R. Bottero, A. Di Sapio, and M.T. Giordana Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients Neurology 60 2003 634
4. F. Deisenhammer, M. Reindl, J. Harvey, T. Gasse, E. Dilitz, and T. Berger Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies Neurology 52 1999 1239
5. F. Deisenhammer, H. Schellekens, and A. Bertolotto Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis J. Neurol. 251 Suppl 2 2004 II31
6. J.G. Files, J.L. Gray, L.T. Do, W.P. Foley, J.D. Gabe, E. Nestaas, and E. Pungor Jr. A novel sensitive and selective bioassay for human type I interferons J. Interferon Cytokine Res. 18 1998 1019
7. J.A. Frank, N. Richert, C. Bash, L. Stone, P.A. Calabresi, B. Lewis, R. Stone, T. Howard, and H.F. McFarland Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients Neurology 62 2004 719
8. F. Gilli, A. Sala, F. Marnetto, R.L. Lindberg, D. Leppert, and A. Bertolotto Comparison of IFNbeta bioavailability evaluations by MxA mRNA using two independent quantification methods Abstract, ECTRIMS Meeting, Milan, Italy 2003
9. F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R.L. Lindberg, and D. Leppert Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs Brain 127 2004 259
10. F. Gilli, F. Marnetto, M. Caldano, A. Sala, S. Malucchi, A. Di Sapio, M. Capobianco, and A. Bertolotto Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis J. Neuroimmunol. 158 2005 195
11. C. Gneiss, M. Reindl, A. Lutterotti, R. Ehling, R. Egg, M. Khalil, T. Berger, and F. Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Mult. Scler. 10 2004 507
12. S.E. Grossberg, Y. Kawade, M. Kohase, and J.P. Klein The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit J. Interferon Cytokine Res. 21 2001 743
13. Y. Kawade Quantitation of neutralization of interferon by antibody Methods Enzymol. 119 1986 558
14. A. Kracke, P. von Wussow, A.N. Al-Masri, G. Dalley, A. Windhagen, and F. Heidenreich Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS Neurology 54 2000 193
15. N. Lawrence, J. Oger, T. Aziz, J. Palace, and A. Vincent A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta J. Neurol. Neurosurg. Psychiatry 74 2003 1236
16. S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis Neurology 62 2004 2031
17. E. Mizukoshi, S. Kaneko, K. Kaji, S. Terasaki, E. Matsushita, M. Muraguchi, Y. Ohmoto, and K. Kobayashi Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C Hepatology 30 1999 1325
18. E. Nestaas, J.G. Files, J.W. Nelson, and E. Pungor Jr. Quantitation and characterisation of multiple sclerosis antibodies to interferon-b A.T. Reder Interferon Therapy of Multiple Sclerosis 1996 Marcel Dekker New York 523
19. A. Pachner, K. Narayan, N. Price, M. Hurd, and D. Dail MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity Mol. Diagn. 7 2003 17
20. A.R. Pachner, A. Bertolotto, and F. Deisenhammer Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB) Neurology 61 2003 S24
21. H. Panitch, D.S. Goodin, G. Francis, P. Chang, P.K. Coyle, P. O'Connor, E. Monaghan, D. Li, and B. Weinshenker Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496
22. M. Pawlowski, M. Lerner, J. Goyal, V. Jethwa, and M. Subramanyam Determination of neutralizing antibodies to interferon beta (IFN-beta): by analyzing inhibition of IFN-beta mediated MxA induction Abstract, ISICR Meeting, Cairns, Australia 2003
23. P. Perini, M. Calabrese, G. Biasi, and P. Gallo The clinical impact of interferon beta antibodies in relapsing-remitting MS J. Neurol. 251 2004 305
24. A.J. Petkau, R.A. White, G.C. Ebers, A.T. Reder, W.A. Sibley, F.D. Lublin, and D.W. Paty Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis Mult. Scler. 10 2004 126
25. J.T. Phillips, G. Rice, E. Frohman, L. Vande Gaer, T. Scott, J. Haas, E. Eggenberger, M.S. Freedman, W. Stuart, L. Cunha, L. Jacobs, J. Oger, D. Arnold, T.J. Murray, M. DiBiase, V. Jethwa, and S. Goelz A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis Clin. Ther. 26 2004 511
26. PRISMS Study Group PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS Neurology 56 2001 1628
27. E. Pungor Jr., J.G. Files, J.D. Gabe, L.T. Do, W.P. Foley, J.L. Gray, J.W. Nelson, E. Nestaas, J.L. Taylor, and S.E. Grossberg A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b J. Interferon Cytokine Res. 18 1998 1025
28. G.P. Rice, B. Paszner, J. Oger, J. Lesaux, D. Paty, and G. Ebers The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b Neurology 52 1999 1277
29. R.A. Rudick, N.A. Simonian, J.A. Alam, M. Campion, J.O. Scaramucci, W. Jones, M.E. Coats, D.E. Goodkin, B. Weinstock-Guttman, R.M. Herndon, M.K. Mass, J.R. Richert, A.M. Salazar, F.E. Munschauer III, D.L. Cookfair, J.H. Simon, and L.D. Jacobs Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 50 1998 1266
30. P.S. Sorensen, C. Ross, K.M. Clemmesen, K. Bendtzen, J.L. Frederiksen, K. Jensen, O. Kristensen, T. Petersen, S. Rasmussen, M. Ravnborg, E. Stenager, and N. Koch-Henriksen Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184
31. A.M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, and J.P. Eralinna Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients Neurology 58 2002 1786
32. T.K. Vartanian, S.S. Zamvil, E. Fox, and P.S. Sorensen Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis Neurology 63 2004 S42
33. World Health Organisation Expert Committee on Biological Standardisation Thirty-fifth Report World Health Organisation Technical Report Series vol. 725 1985 World Health Organisation Geneva, Switzerland